AstraZeneca

45 YEARS
Bringing science to patients since 1979

August 11, 2026

The Manager – Listing
BSE Limited
P J Towers, Dalal Street, Fort,
Mumbai 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sirs/ Madam,

Sub: Press Release

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

In line with Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release for the quarter ended June 30, 2026.

Please note that, the phrase "Profit after exceptional item and tax" appearing in the financial performance summary is to be read as "Profit after exceptional item and before tax" (i.e. Profit before tax).

Thanking you,

For **AstraZeneca Pharma India Limited**

TANYA SANISH
Digitally signed by TANYA SANISH
Date: 2026.08.11 00:36:32 +05'30'

Tanya Sanish
Company Secretary & Compliance Officer

News Release

AstraZeneca

AstraZeneca Pharma India maintains growth momentum with a strong start to FY2026–27, driven by the strength of our portfolio

Q1 FY2026–27 performance reflects disciplined execution across core therapy areas, important regulatory milestones and strategic partnerships that are helping expand access to innovative healthcare solutions in India

10 August 2026: AstraZeneca Pharma India Limited ("the Company"), a science-led biopharmaceutical company, today announced its financial results for the quarter ended **June 30, 2026**, reporting **30%** growth in total revenue from operations to **INR 6,828 Mn** in **Q1 FY2026–27**. The Company's performance was driven by continued momentum across its core therapy areas-- **Oncology**, **Biopharmaceuticals (CVRM and R&I)** and **Rare Disease**, reflecting the strength of its innovation-led strategy, disciplined execution and focus on improving patient outcomes in India.

During the quarter, the Company strengthened its portfolio through key regulatory approvals, expanded scientific engagement through targeted capability-building initiatives and advanced strategic partnerships that support earlier diagnosis and broader access. These developments reflect AstraZeneca Pharma India's continued focus on addressing unmet medical needs, deepening its presence across priority therapy areas and creating long-term value through science, innovation and sustainable growth.

Financial performance summary:

(Value in INR Mn)

Summary	Q1 2026-27 April-June 2026 (Absolute numbers)
Total revenue from Operations	6,828
Profit before exceptional item and tax	510
Profit after exceptional item and tax	507

TA-wise performance		
Summary	**Q1 2026-27 April-June 2026 (Absolute numbers)**	**Growth vs Q1 2025 -26**
Oncology	4,649	26%
Biopharmaceuticals (CVRM, R&I and V&I)	1,619	36%
Rare Diseases	144	35x

Bhavana Agrawal, Chief Financial Officer & Director of the Company, said, *"We delivered 30% growth in the first quarter, bringing our revenue to INR 6,828 Mn. This performance builds on our strong track record of delivering a consistent double-digit growth over the last five years. Our focus remains on investing strategically in opportunities that support sustainable long-term value creation."*

Mr. Praveen Rao Akkinepally, Country President & Managing Director, AstraZeneca Pharma India Ltd., added, *"Our purpose is to push the boundaries of science to deliver life-changing medicines, and this shapes how we serve unmet patient needs in India. The growth and momentum in the first quarter reflects the strength of our portfolio and focus on expanding access to serve more patients in India."*

Key milestones:

- **Acalabrutinib – Chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL):** Received regulatory approval for **acalabrutinib in combination with venetoclax with or without obinutuzumab** for the treatment of patients with previously untreated **chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL)**.
- **Acalabrutinib – Mantle cell lymphoma (MCL):** Received regulatory approval for **acalabrutinib in combination with bendamustine and rituximab** for the treatment of adult patients with previously untreated **mantle cell lymphoma (MCL)** who are not eligible for **autologous stem cell transplant (ASCT)**.
- **Trastuzumab deruxtecan – HER2-positive breast cancer:** Received regulatory approval for **trastuzumab deruxtecan in combination with pertuzumab** for the first-line treatment of adult patients with unresectable or metastatic **HER2-positive (IHC3+ or ISH+) breast cancer**.

Strategic initiatives:

- **Government of Telangana MoU – AI-enabled lung cancer screening:** Signed a **Memorandum of Understanding with the Government of Telangana** to introduce **AI-enabled lung cancer screening** across public healthcare facilities in the state. Under the collaboration, AstraZeneca will facilitate deployment of **Qure.ai's AI-powered chest X-ray solution** to support clinicians in identifying high-risk pulmonary nodules and other lung conditions, enabling earlier triage and follow-up. The initiative is expected to roll out across **20 public health facilities** spanning urban and rural settings and includes training and upskilling of healthcare professionals to support effective and sustainable adoption.
- **K+ Connect – Hyperkalaemia management in Heart Failure and Chronic Kidney Disease:** Launched K+ Connect, a pan-India multidisciplinary initiative focused on advancing the management of hyperkalaemia among patients living with heart failure and chronic kidney disease. The initiative brings together clinicians across specialties to support a more coordinated approach towards risk identification, monitoring and management of hyperkalaemia.
- **India Coronary Conquest (ICC) 2026 – Advancing cardiovascular care:** Launched India Coronary Conquest 2026 in collaboration with STEMI India, a clinician-led national complex PCI challenge designed to strengthen evidence-based learning and peer exchange among interventional cardiologists. The initiative aims to support capability building in advanced cardiovascular care through case-based learning and scientific collaboration.

Recognitions:

- **OPPI India Awards 2026:** AstraZeneca Pharma India received the **Medical Excellence Award** for its contributions to Rare Disease and was named **Runner-up in the Marketing Excellence** category for its Hyperkalaemia & Kidney Care initiative in Biopharmaceuticals.
- **ETHRWorld Employee Experience Awards 2026:** AstraZeneca Pharma India was awarded the **Gold Award** in the **Exceptional Employee Experience in Driving Business Impact** category, recognising its commitment to fostering a high-performing, collaborative and purpose-driven workplace.

About AstraZeneca Pharma India Ltd

AstraZeneca Pharma India Limited (AZPIL) is the listed operating company of AstraZeneca in India. A science-led biopharmaceutical company, it focuses on the discovery, development and commercialisation of prescription medicines across key therapy areas including **Oncology**, **Biopharmaceuticals** and **Rare Disease**. With a workforce of over **600 employees** across the country, AZPIL is committed to advancing innovative science, expanding access to differentiated medicines and contributing meaningfully to patient care through strong commercial execution and partnerships across the healthcare ecosystem.